Freenome
Freenome raises $290M Series D at $1.1B valuation
Freenome: Series D Funding Round
Freenome has successfully raised $290M in Series D funding, reaching a valuation of $1.1B.
Company Overview
AI-driven early cancer detection
Funding Details
The Series D round was led by Perceptive Advisors, with participation from RA Capital Management, Andreessen Horowitz, GV, T. Rowe Price, Roche Venture Fund.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2014
- Employees: 400+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Perceptive Advisors: Verified investor in Series D
- RA Capital Management: Verified investor in Series D
- Andreessen Horowitz: Verified investor in Series D
- GV: Verified investor in Series D
- T. Rowe Price: Verified investor in Series D
- Roche Venture Fund: Verified investor in Series D
Company Info
Investors (6)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free